Selection of a fully human single domain antibody specific to Helicobacter pylori urease.


Journal

Applied microbiology and biotechnology
ISSN: 1432-0614
Titre abrégé: Appl Microbiol Biotechnol
Pays: Germany
ID NLM: 8406612

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 07 09 2018
accepted: 30 01 2019
revised: 29 01 2019
pubmed: 28 2 2019
medline: 26 7 2019
entrez: 28 2 2019
Statut: ppublish

Résumé

Helicobacter pylori bacteria are involved in gastroduodenal disorders, including gastric adenocarcinoma. Since the current therapies encounter with some significant shortcomings, much attention has been paid to the development of new alternative diagnostic and treatment modalities such as immunomedicines to target H. pylori. Having used phage display technology, we isolated fully humane small antibody (Ab) fragment (V

Identifiants

pubmed: 30810777
doi: 10.1007/s00253-019-09674-6
pii: 10.1007/s00253-019-09674-6
doi:

Substances chimiques

Antibodies, Bacterial 0
Bacterial Proteins 0
Enzyme Inhibitors 0
Peptide Library 0
Single-Domain Antibodies 0
Urease EC 3.5.1.5

Types de publication

Journal Article

Langues

eng

Pagination

3407-3420

Subventions

Organisme : Tabriz University of Medical Sciences
ID : RCPN-93006

Auteurs

Mehdi Fouladi (M)

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
School of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Pharmaceutical Sciences Research Center, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Shamim Sarhadi (S)

School of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammadreza Tohidkia (M)

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. tohidkia86@yahoo.com.

Farnaz Fahimi (F)

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
School of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Naser Samadi (N)

School of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Javid Sadeghi (J)

Department of Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Jaleh Barar (J)

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Yadollah Omidi (Y)

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. yomidi@tbzmed.ac.ir.
School of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. yomidi@tbzmed.ac.ir.
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. yomidi@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH